Style | Citing Format |
---|---|
MLA | Abbasian L, et al.. "Comparing Efficacy and Safety of Tocilizumab and Methylprednisolone in the Treatment of Patients With Severe Covid-19." International Immunopharmacology, vol. 107, no. , 2022, pp. -. |
APA | Abbasian L, Toroghi N, Rahmani H, Khalili H, Hasannezhad M, Ghiasvand F, Jafari S, Salehi M, Salahshour F, Azadbakhsh Kanaf Gorabi M, Alizade F, Ghaderkhani S, Nakhostin M (2022). Comparing Efficacy and Safety of Tocilizumab and Methylprednisolone in the Treatment of Patients With Severe Covid-19. International Immunopharmacology, 107(), -. |
Chicago | Abbasian L, Toroghi N, Rahmani H, Khalili H, Hasannezhad M, Ghiasvand F, Jafari S, et al.. "Comparing Efficacy and Safety of Tocilizumab and Methylprednisolone in the Treatment of Patients With Severe Covid-19." International Immunopharmacology 107, no. (2022): -. |
Harvard | Abbasian L et al. (2022) 'Comparing Efficacy and Safety of Tocilizumab and Methylprednisolone in the Treatment of Patients With Severe Covid-19', International Immunopharmacology, 107(), pp. -. |
Vancouver | Abbasian L, Toroghi N, Rahmani H, Khalili H, Hasannezhad M, Ghiasvand F, et al.. Comparing Efficacy and Safety of Tocilizumab and Methylprednisolone in the Treatment of Patients With Severe Covid-19. International Immunopharmacology. 2022;107():-. |
BibTex | @article{ author = {Abbasian L and Toroghi N and Rahmani H and Khalili H and Hasannezhad M and Ghiasvand F and Jafari S and Salehi M and Salahshour F and Azadbakhsh Kanaf Gorabi M and Alizade F and Ghaderkhani S and Nakhostin M}, title = {Comparing Efficacy and Safety of Tocilizumab and Methylprednisolone in the Treatment of Patients With Severe Covid-19}, journal = {International Immunopharmacology}, volume = {107}, number = {}, pages = {-}, year = {2022} } |
RIS | TY - JOUR AU - Abbasian L AU - Toroghi N AU - Rahmani H AU - Khalili H AU - Hasannezhad M AU - Ghiasvand F AU - Jafari S AU - Salehi M AU - Salahshour F AU - Azadbakhsh Kanaf Gorabi M AU - Alizade F AU - Ghaderkhani S AU - Nakhostin M TI - Comparing Efficacy and Safety of Tocilizumab and Methylprednisolone in the Treatment of Patients With Severe Covid-19 JO - International Immunopharmacology VL - 107 IS - SP - EP - PY - 2022 ER - |